CONTACT US

Skyepharma is a specialist CDMO

for the development and manufacturing of complex oral solid forms for controlled release applications.

  • Tab-in-tab
  • Multi-layer tablets
  • Enteric capsules

Fully integrated CDMO offering tailor-made solutions

We provide tailor-made solutions to our customers by positioning ourselves as a fully integrated CDMO offering a wide range of premium services.


Our experienced team of specialists works to optimize target product profile and drug development program from early formulation development, scale-up, manufacturing and packaging to regulatory support.

CDMO center of excellence in Development

Formulation development

We have extensive experience in solving complex formulation challenges. Our experts will advise you on the best solution to optimise drug delivery for the benefit to the patients. We could include our range of proprietary technologies to provide modified, pulse or timed release profiles  to solve technological challenges, to provide patient benefits and to offer additional proprietary protection to the product.

Prototyping

We perform rapid and flexible prototyping essays to early characterized powders leading to anticipate potential up scaling issues which lead to save time and money.


Our key differentiators regards our compression simulator (Styl’One Evolution) and low scale equipment which reproduce industrial processes such as wet granulation, compression including tabletting and roller compaction and coating.

Product manufacturing for clinical trial

Once formulation is validated, we use our cGMP facilities to supply product for clinical study. Regulatory support is provided to assist you during clinical phases.

Controlled release technologies

Oral Drug Delivery Technologies

Skyepharma controlled release expertise is the result of years as a leader in drug development and oral drug delivery technologies serving the global pharmaceutical industry. Since it was founded, Skyepharma has had a strong focus on oral drug delivery, solving the many challenges of delivering the right dose of a drug to the right part of the gastrointestinal system for absorption at the right time and at the appropriate rate to achieve the desired therapeutic effect.

Oral Patented Technologies

3 patented pharmaceutical technologies: Geomatrix®, Geoclock®,and Soctec®. These platforms allow us to build controlled release formulations to adapt to patient dosing schedules or adjust API intake. These proprietary technologies allow us to better manage side effects

Brand new packaging lines - Serialization & aggregation: 

Since 2018, oral dosage CDMO Skyepharma radically updated and expanded its packaging capabilities, opening new packaging lines equipped for serialization and aggregation.  

WE ARE AVAILABLE FOR YOU

CONTACT US

Go to article: Home | Waive goodbye to vaccine patentsGo to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: DatwylerGo to article: Datwyler Company InsightGo to article: LabcorpGo to article: Biesterfeld Go to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Dr. Paul LohmannGo to article: ButterworthGo to article: SkyepharmaGo to article: BaxterGo to article: CommentGo to article: Speeding up patient access to innovative drugsGo to article: The competitive landscape of neoantigen-targeting therapeutics in oncologyGo to article: Bacterial “cell factories”: an eco-friendly approach to chemical productionGo to article: MDR set to transform how MedTech firms approach content managementGo to article: PerkinElmerGo to article: NiproGo to article: NiproGo to article: In DepthGo to article: Should UK children be vaccinated against chickenpox?Go to article: Fighting India’s ‘black fungus’ epidemicGo to article: What could a vaccine patent waiver mean for pharma manufacturing? Go to article: Algae proteins: a vision of the futureGo to article: A brief history of ALS awareness and its sparse treatments Go to article: Ferring draws closer to a microbiome breakthroughGo to article: The Solubility companyGo to article: Myonex Go to article: Owen MumfordGo to article: In DataGo to article: Data: pharma subsidiaries Go to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue